PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998
- PMID:11453328
- DOI: 10.5694/j.1326-5377.2001.tb143436.x
PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998
Abstract
Objectives: To determine the extent to which "current guidelines" for the management of hypertension are reflected in the prescribing of antihypertensive drugs in Australia over the period 1994-1998, and to examine the cost implications of actual and recommended prescribing patterns.
Design: Federal Government and consumer cost estimates modelled on prescribing patterns and guideline recommendations over the period 1994-1998.
Setting: Prescribing on Federal Government pharmaceutical schemes over the 1994-1998 period.
Main outcome measures: Estimates of Pharmaceutical Benefits Scheme/Repatriation Pharmaceutical Benefits Scheme cost changes in Australian dollar values.
Results: The implementation of current guidelines for patients with uncomplicated hypertension taking monotherapy alone could have reduced drug costs by $45-$108 million in 1998.
Conclusions: Current prescribing patterns indicate that clinical practice has pre-empted the results from clinical trials of newer, more expensive agents and that clinicians' prescribing patterns do not closely reflect current recommendations.
Comment in
- Containing the costs of managing hypertension.Arnolda L.Arnolda L.Med J Aust. 2001 Jun 4;174(11):556-7. doi: 10.5694/j.1326-5377.2001.tb143432.x.Med J Aust. 2001.PMID:11453324Review.No abstract available.
- PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension.Ewald BD, Pekarsky B.Ewald BD, et al.Med J Aust. 2002 Feb 18;176(4):189; author reply 190. doi: 10.5694/j.1326-5377.2002.tb04357.x.Med J Aust. 2002.PMID:11913924No abstract available.
Similar articles
- Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure.Siegel D, Lopez J.Siegel D, et al.JAMA. 1997 Dec 3;278(21):1745-8. doi: 10.1001/jama.278.21.1745.JAMA. 1997.PMID:9388150
- The influence of the Pharmaceutical Benefits Scheme (PBS) on inappropriate prescribing in Australian nursing homes.King MA, Roberts MS.King MA, et al.Pharm World Sci. 2007 Feb;29(1):39-42. doi: 10.1007/s11096-005-5618-9.Pharm World Sci. 2007.PMID:17268937
- Population impact of the 2017 ACC/AHA guidelines compared with the 2013 ESH/ESC guidelines for hypertension management.Vaucher J, Marques-Vidal P, Waeber G, Vollenweider P.Vaucher J, et al.Eur J Prev Cardiol. 2018 Jul;25(10):1111-1113. doi: 10.1177/2047487318768938. Epub 2018 Apr 11.Eur J Prev Cardiol. 2018.PMID:29637794
- Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension.Klarenbach SW, McAlister FA, Johansen H, Tu K, Hazel M, Walker R, Zarnke KB, Campbell NR; Canadian Hypertension Education Program.Klarenbach SW, et al.Can J Cardiol. 2010 May;26(5):e158-63. doi: 10.1016/s0828-282x(10)70383-4.Can J Cardiol. 2010.PMID:20485695Free PMC article.Review.
- Medication prescribing advice and drug utilization: a review from the United Kingdom.Law J, Thompson A.Law J, et al.Pharm Pract Manag Q. 1996 Jan;15(4):27-35.Pharm Pract Manag Q. 1996.PMID:10153842Review.
Cited by
- Prescribing Data in General Practice Demonstration (PDGPD) project--a cluster randomised controlled trial of a quality improvement intervention to achieve better prescribing for chronic heart failure and hypertension.Williamson M, Cardona-Morrell M, Elliott JD, Reeve JF, Stocks NP, Emery J, Mackson JM, Gunn JM.Williamson M, et al.BMC Health Serv Res. 2012 Aug 23;12:273. doi: 10.1186/1472-6963-12-273.BMC Health Serv Res. 2012.PMID:22913571Free PMC article.Clinical Trial.
- Clinical and nonclinical correlates of adherence to prescribing guidelines for hypertension in a large managed care organization.Skelding PC, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, Prosser L, Simon SR.Skelding PC, et al.J Clin Hypertens (Greenwich). 2006 Jun;8(6):414-9. doi: 10.1111/j.1524-6175.2006.05337.x.J Clin Hypertens (Greenwich). 2006.PMID:16760680Free PMC article.
- The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis.Fretheim A, Aaserud M, Oxman AD.Fretheim A, et al.BMC Health Serv Res. 2003 Sep 8;3(1):18. doi: 10.1186/1472-6963-3-18.BMC Health Serv Res. 2003.PMID:12959644Free PMC article.
- Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study.Montgomery BD, Mansfield PR, Spurling GK, Ward AM.Montgomery BD, et al.BMC Public Health. 2008 May 20;8:167. doi: 10.1186/1471-2458-8-167.BMC Public Health. 2008.PMID:18492241Free PMC article.
- Budget impact analysis of the adoption of new hypertension guidelines in Colombia.Guevara-Cuellar CA, Soto VE, Molina-Echeverry MI.Guevara-Cuellar CA, et al.Cost Eff Resour Alloc. 2018 Sep 25;16:32. doi: 10.1186/s12962-018-0152-5. eCollection 2018.Cost Eff Resour Alloc. 2018.PMID:30263015Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical